Print Page   |   Sign In   |   Become a Member
Site Search
Experimental Hematology
Blog Home All Blogs
Search all posts for:   


Inside this Issue: July/August

Posted By Connections Editor, Friday, August 19, 2016
Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms
Anna-Sophia Wiekmeijer, Karin Pike-Overzet, Martijn H. Brugman, Marja C.J.A. van Eggermond, Martijn Cordes, Edwin F.E. de Haas, Yunlei Li, Edwin Oole, Wilfred F.J. van IJcken, R. Maarten Egeler, Jules P. Meijerink, Frank J.T. Staal

HnRNP K contributes to drug resistance in acute myeloid leukemia through the regulation of autophagy
JinFang Zhang, XiaoLi Liu, YuDeng Lin, YuLing Li, JianWei Pan, Sa Zong, YongKang Li, Yang Zhou

Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women
Julia Erin Wiedmeier, Catherine Kato, Zhenzhen Zhang, Hyunjung Lee, Jennifer Dunlap, Eric Nutt, Rogan Rattray, Sarah McKay, Christopher Eide, Richard Press, Motomi Mori, Brian Druker, Kim-Hien Dao

Long-term adaptation to hypoxia preserves hematopoietic stem cell function
Jichun Chen, Ju-Gyeong Kang, Keyvan Keyvanfar, Neal S. Young, Paul M. Hwang

A novel lymphoid progenitor cell population (LSKlow) is restricted by p18INK4c
Fang Dong, Sha Hao, Shihui Ma, Hui Cheng, Yajie Wang, Wen Zhou, Weiping Yuan, Hideo Ema, Tao Cheng

Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML
Lacramioara Botezatu, Lars C. Michel, Anne Helness, Charles Vadnais, Hideki Makishima, Judith M. Hönes, François Robert, Lothar Vassen, Aniththa Thivakaran, Yahya Al-Matary, Robert F. Lams, Judith Schütte, Bernd Giebel, André Görgens, Michael Heuser, Hind Medyouf, Jaroslaw Maciejewski, Ulrich Dührsen, Tarik Möröy, Cyrus Khandanpour

Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice

Marie-Lorraine Chrétien, Caroline Legouge, Romain Z. Martin, Arlette Hammann, Malika Trad, Romain Aucagne, Anne Largeot, Jean-Noël Bastie, Laurent Delva, Ronan Quéré

Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia
Moe Kadono, Akinori Kanai, Akiko Nagamachi, Satoru Shinriki, Jin Kawata, Koji Iwato, Taiichi Kyo, Kumi Oshima, Akihiko Yokoyama, Takeshi Kawamura, Reina Nagase, Daichi Inoue, Toshio Kitamura, Toshiya Inaba, Tatsuo Ichinohe, Hirotaka Matsui

A dimeric peptide with erythropoiesis-stimulating activity uniquely affects erythropoietin receptor ligation and cell surface expression
Rakesh Verma, Jennifer M. Green, Peter J. Schatz, Don M. Wojchowski

This post has not been tagged.

Share |
PermalinkComments (0)

Inside this Issue: May/June

Posted By Connections Editor, Thursday, June 16, 2016


Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study
Jie Ji, Benigno C. Valdez, Yang Li, Yan Liu, Esmeralda C. Teo, Yago Nieto, Richard E. Champlin, Borje S. Andersson

  • Cladribine, gemcitabine, busulfan, and SAHA (suberoylanilide hydroxamic acid) exert synergistic effects in lymphoma cell lines.
  • This combination activates DNA damage response and apoptosis.
  • Pre-exposure to SAHA improves drug efficacy.
  • This combination may be used as the basis for a clinical trial of stem cell transplantation for lymphoma patients. 

A preliminary study on epigenetic regulation of Acanthopanax senticosus in leukemia cell lines
Qing-Yuan Wang, Hua Zhong, Fang-Yuan Chen, Min-Yue Zhang, Jia-Yi Cai, Ji-Hua Zhong

  • Acanthopanax senticosus induced apoptosis of human leukemia HL-60 and HL60/ADM cells in a dose- and time-dependent manner.
  • Acanthopanax senticosus promoted histone H3 acetylation by inhibiting histone deacetyltransferase activity.
  • Acanthopanax senticosus induced FasL expression in HL60/ADM cells, probably through histone H3 promotion. 

SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders
Matthew M. Hsieh, David Callacondo, Jose Rojas-Camayo, Jose Quesada-Olarte, Xunde Wang, Naoya Uchida, Irina Maric, Alan T. Remaley, Fabiola Leon-Velarde, Francisco C. Villafuerte, John F. Tisdale

  • Higher hemoglobin levels consistently distinguish persons with chronic mountain sickness from healthy persons.
  • Fetal hemoglobin levels of all Andean highlanders (with and without chronic mountain sickness) were similar to the levels of fetal hemoglobin found in persons at sea level.
  • Classic hypoxia inducible factor regulated EPAS1 and EGLN1 were also similar in healthy Andean highlanders and those with chronic mountain sickness.
  • SENP1 may play a role in Andean high-altitude adaptation.

Quantitative analysis of dietary iron utilization for erythropoiesis in response to body iron status
Yukari Matsuo-Tezuka, Mariko Noguchi-Sasaki, Mitsue Kurasawa, Keigo Yorozu, Yasushi Shimonaka 

  • 57Fe is a useful tool in tracing dietary iron.
  • The contribution of dietary iron to erythropoiesis can be quantified by 57Fe.
  • Stored iron is preferentially used for erythropoiesis under conditions of iron loading.
  • Regulation of iron release is tissue specific.

The frequency of multipotent CD133+CD45RA−CD34+ hematopoietic stem cells is not increased in fetal liver compared with adult stem cell sources 

Stefan Radtke, Kevin G. Haworth, Hans-Peter Kiem 

  • Multipotent hematopoietic stem cells are not increased in human fetal liver compared with adult tissues.
  • The lymphomyeloid and erythromyeloid lineages are segregated in fetal hematopoiesis.
  • Fetal liver hematopoietic stem cells/multipotent progenitors are primed for erythromyeloid lineage specification.
  • NOD/SCID mouse engraftment is driven mostly by lymphomyeloid-restricted, lymphomyeloid-primed progenitors. 

Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells
Patrick Wuchter, Marcel Vetter, Rainer Saffrich, Anke Diehlmann, Karen Bieback, Anthony D. Ho, Patrick Horn

  • Xeno-free human platelet lysate-based cell expansion of human bone marrow-derived mesenchymal stromal cells (MSCs) was comprehensively analyzed and directly compared with two commercially available media: StemPro MSC SFM CTS (for human ex vivo tissue and cell culture processing applications) and MSCGM (non-GMP-compliant, for research only).
  • Quantitative and qualitative analysis of the resulting cell populations included assessment of proliferation kinetics, differentiation capacity, cell morphology, and immunophenotype.
  • A blueprint for an MSC-expansion strategy on a clinically relevant scale is presented.
  • Cost analyses for MSC expansion strategies with all three media were assessed.


Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma
Stina Wichert, Åsa Pettersson, Thomas Hellmark, Åsa Johansson, Markus Hansson

  • We examined changes in phagocyte phenotype and function after ASCT in MM patients.
  • PMNs showed reduced capacity for phagocytosis and oxidative burst.
  • Eosinophils were markedly reduced and slow to regenerate.
  • HLA-DR expression by monocytes was significantly depressed.
  • Several aspects of phagocytic functions are affected in MM patients after ASCT.

Leukemia and chromosomal instability in aged Fancc−/− mice
Donna Cerabona, Zejin Sun, Grzegorz Nalepa

  • Aging Fancc−/− mice are prone to hematopoietic malignancies
  • Chromosomal abnormalities in hematopoietic Fancc−/− cells precede the development of leukemia
  • Fancc−/− leukemia can be successfully transplanted into healthy wt recipients 

Expression of surface-associated 82kDa-proMMP-9 in primary acute leukemia blast cells inversely correlates with patients' risk 
Joerg Schmohl, Donato Santovito, Thomas Guenther, Wishnu Sutanto, Tanja Kroell, Helmut Salih, Thomas Pitsch, Virginia Egea, Christian Weber, Helga Schmetzer, Christian Ries 

  • Monoclonal antibodies have been generated that specifically detect a unique cell surface-associated MMP-9 variant.
  • The MMP-9 variant is present in monocytes and acute myeloid leukemia blasts, but is scarce in T cells and B cells.
  • High expression levels of MMP-9 variant in acute myeloid leukemia blasts correlate with a favorable risk for patients. 


    Phenotypic, genotypic, and functional characterization of normal and acute myeloid leukemia-derived marrow endothelial cells
    Russell J. Pizzo, Mitra Azadniv, Naxin Guo, Joshua Acklin, Kimberly Lacagnina, Myra Coppage, Jane L. Liesveld

    • Endothelial cells can be cultured from acute myeloid leukemia (AML)-derived marrow, but these grew more slowly and exhibited increased senescence, as measured by β-galactosidase staining, compared with endothelial cells cultured from normal subject-derived marrow.
    • AML-derived marrow endothelial cells expressed endothelial markers and surface adhesion receptors similar to those of normal subject-derived marrow endothelial cells; the AML-derived cells had similar transmigration and clonogenic support capacity, but increased adhesion of leukemia blasts.
    • RNA sequencing revealed 130 genes differentially expressed between AML-derived and normal subject-derived marrow endothelial cells, including significant upregulation of c-fos and CXCL16.

    Insulin-like growth factor 2 modulates murine hematopoietic stem cell maintenance through upregulation of p57 

    Dolly D. Thomas, Andreia Gianotti Sommer, Alejandro B. Balazs, Isabel Beerman, George J. Murphy, Derrick Rossi, Gustavo Mostoslavsky

    • Insulin-like growth factor 2 (IGF2) is preferentially expressed in long-term hematopoietic stem cells (HSCs).
    • Within HSCs, IGF2 activates the PI3K-Akt pathway to upregulate expression of p57.
    • HSCs exhibit decreased methylation at CpG sites within the p57 gene promoter.
    • The described mechanism illustrates a novel regulatory function for IGF2 in HSCs.



    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside this Issue: March/April

    Posted By Connections Editor, Thursday, April 14, 2016
    Updated: Monday, April 11, 2016


    Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach
    Elliot M. Epner, Bikramajit Singh Saroya, Zainul S. Hasanali, Thomas P. Loughran  

    • Cladribine, histone deacetylase inhibitor, and alemtuzumab constitute an effective therapy for T-cell prolymphocytic leukemia.
    • Cladribine and histone deacetylase inhibitor induce CD30 and allow for brentuximab vedotin therapy in T-cell prolymphocytic leukemia.
    • The combination of DNA methyltransferase inhibitor, histone deacetylase inhibitor, and monoclonal antibody therapy is an effective treatment paradigm for cancer.
    • Antibody-dependent cell-mediated cytotoxicity is central to the mechanism of action of monoclonal antibody therapy.

    CD44 promotes chemoresistance in T-ALL by increased drug efflux
    Catherine Hoofd, Xuehai Wang, Sonya Lam, Catherine Jenkins, Brent Wood, Vincenzo Giambra, Andrew P. Weng 

    • Chemotherapy selected for increased CD44 expression in a mouse model of T-cell acute lymphoblastic leukemia (T-ALL).
    • Enforced CD44 expression in mouse and human T-ALL cells enhanced chemoresistance.
    • CD44 knockdown or treatment with blocking antibody enhanced chemosensitivity.
    • CD44 enhanced drug efflux activity in human T-ALL cells.
    • Patients undergoing induction chemotherapy had elevated CD44 levels in residual blasts.

    Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia
    Wen Tian Sun, Wei Xiang, Bee Ling Ng, Kartini Asari, Ralph M. Bunte, Patrick J. Casey, Mei Wang, Charles Chuah 

    • Isoprenylcysteine carboxylmethyltransferase inhibition enhances the effect of BCR-ABL tyrosine kinase inhibition.
    • Cysmethynil, an isoprenylcysteine carboxylmethyltransferase inhibitor, augments tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells.
    • The combination of cysmethynil and imatinib inhibits colony formation in primary chronic myeloid leukemia cells.
    • The in vivo effects of the cysmethynil/imatinib combination are enhanced compared with the effects of either drug alone.
    • Enhanced apoptosis may be caused by immediate and persistent inhibition of MAPK signaling.

    Fms-like tyrosine kinase 3 (Flt3) ligand depletes erythroid island macrophages and blocks medullar erythropoiesis in the mouse
    Rebecca N. Jacobsen, Bianca Nowlan, Marion E. Brunck, Valerie Barbier, Ingrid G. Winkler, Jean-Pierre Levesque

    • Daily administration of Flt3 ligand in mice depletes erythroblastic island macrophages and inhibits erythropoiesis in the bone marrow.
    • Suppression of medullary erythropoiesis is compensated by increases in erythroblastic island macrophage numbers and erythropoiesis in the spleen.
    • The suppressive effect of Flt3 ligand on medullary erythroblastic island macrophages and erythropoiesis is likely to be indirect, as
    • Flt3 receptor is not expressed by macrophages or erythroid progenitors.



    Ex vivo evaluation of the effect of regulatory T cells on the anti-tumor activity of bortezomib in multiple myeloma
    Ayse Pinar Ercetin, Mehmet Ali Ozcan, Safiye Aktas, Faize Yuksel, Serife Medeni Solmaz, Gokmen Omur Sevindik, Abdullah Katgi, Ozden Piskin, Bulent Undar

    • A primary multiple myeloma cell culture and a co-culture with host Treg cells were established.
    • The interaction between Treg cell expansion and the anti-tumor effect of bortezomib was revealed.
    • Treg cells had varied effects on bortezomib, increasing, decreasing, or not changing its anti-tumor effect on multiple myeloma.
    • Treg cells increased the ex vivo anti-tumor effect of bortezomib in patients who did not develop bortezomib resistance in vivo.
    • Treg cells decreased the ex vivo anti-tumor effect of bortezomib in patients who developed bortezomib resistance in vivo. 

    Expression of the MOZ-TIF2 oncoprotein in mice represses senescence
    Anne Largeot, Flor Maria Perez-Campo, Elli Marinopoulou, Michael Lie-a-Ling, Valerie Kouskoff, Georges Lacaud

    • MOZ-TIF2 transformation is associated with inhibition of senescence through repression of the CDKN2A locus.
    • MOZ histone acetyltransferase activity of MOZ-TIF2 is required for the inhibition of senescence.
    • MOZ-TIF2 acts on the p53 apoptosis-versus-senescence balance.

    Erythroblast enucleation is a dynein-dependent process
    Isuzu Kobayashi, Kumi Ubukawa, Kotomi Sugawara, Ken Asanuma, Yong-Mei Guo, Junsuke Yamashita, Naoto Takahashi, Kenichi Sawada, Wataru Nunomura

    • Dynein was expressed during terminal differentiation of human erythroblasts.
    • Inhibition of dynein blocked the cell proliferation of colony-forming units–erythroid and enucleation.
    • Dynein was distributed in aggregates on the periphery of the nucleus in erythroblasts.
    • Cell polarization was blocked in the dynein inhibitor-treated erythroblasts.
    • Enucleation of human erythroblasts requires cell polarization by dynein.

    Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak
    Ingrid G. Winkler, Eliza Wiercinska, Valerie Barbier, Bianca Nowlan, Halvard Bonig, Jean-Pierre Levesque 

    • After 2 days of administration of granulocyte colony-stimulating factor, mouse blood contains high levels of serially reconstituting hematopoietic stem cells.
    • In mice, mobilization of serially reconstituting hematopoietic stem cells precedes that of clonogenic progenitors.
    • In half of healthy volunteers tested, after 2 days of administration of granulocyte colony-stimulating factor, mobilized CD34+ cells are enriched in CD34+CD38− primitive progenitors.


    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside this Issue: February

    Posted By Connections Editor, Thursday, February 18, 2016

    Hematopoietic niches, erythropoiesis and anemia of chronic infection
    Ana Cordeiro Gomes, Maria Salomé Gomes

    Anemia is a significant co-morbidity of chronic infections, as well as other inflammatory diseases. Anemia of chronic infection results from defective bone marrow erythropoiesis. Although the limitation of iron availability has been considered a key factor, the exact mechanisms underlying blockade in erythroid generation during infection are not fully understood. Erythropoiesis is a tightly regulated process that is very sensitive to environmental changes. During the last decade, the importance of the bone marrow hematopoietic niche has been progressively acknowledged.

    How hematopoietic stem/progenitors and their niche sense and respond to infectious stress

    Hiroshi Kobayashi, Toshio Suda, Keiyo Takubo

    Hematopoietic stem/progenitor cells (HSPCs) play important roles in fighting systemic infection as they supply immune cells in a demand-adapted manner. Various mechanisms govern HSPC responses to infection, including cytokine signaling, niche function, and direct sensing of pathogen-derived molecules by HSPCs themselves. Here we review recent advances in our understanding of HSPC responses to infection and also consider newly identified STING-mediated machinery recognizing bacteria-derived cyclic dinucleotides.

    Hematopoiesis “awakens”: Evolving technologies, the force behind them

    Eugenia Flores-Figueroa, Marieke Essers, Teresa V. Bowman

    Amid the beauty of the Kyoto countryside, leaders in the field of hematology met at the 44th annual International Society for Experimental Hematology (ISEH) meeting in late September 2015. Led by ISEH President Paul Frenette and President-Elect David Traver, the meeting covered many aspects of hematopoiesis with a focus on technology. At the meeting, it became clear that the future of hematology is being shaped by innovations in single-cell “omics” and imaging approaches that will provide answers to age-old questions on cellular identity.

    Kinetics of lentiviral vector transduction in human CD34+ cells

    Naoya Uchida, Rashidah Green, Josiah Ballantine, Luke P. Skala, Matthew M. Hsieh, John F. Tisdale

    Cellular labile iron, which contains chelatable redox-active Fe2+, has been implicated in iron-mediated cellular toxicity leading to multiple organ dysfunction. Iron homeostasis is controlled by monocytes/macrophages through their iron recycling and storage capacities. Furthermore, iron sequestration by monocytes/macrophages is regulated by pro-inflammatory cytokines including interleukin-1, highlighting the importance of these cells in the crosstalk between inflammation and iron homeostasis. However, a role for cellular labile iron in monocyte/macrophage-mediated inflammatory responses has not been defined.

    Activation of the NLRP3 inflammasome by cellular labile iron

    Kyohei Nakamura, Toru Kawakami, Naoki Yamamoto, Miyu Tomizawa, Tohru Fujiwara, Tomonori Ishii, Hideo Harigae, Kouetsu Ogasawara

    Cellular labile iron, which contains chelatable redox-active Fe2+, has been implicated in iron-mediated cellular toxicity leading to multiple organ dysfunction. Iron homeostasis is controlled by monocytes/macrophages through their iron recycling and storage capacities. Furthermore, iron sequestration by monocytes/macrophages is regulated by pro-inflammatory cytokines including interleukin-1, highlighting the importance of these cells in the crosstalk between inflammation and iron homeostasis. However, a role for cellular labile iron in monocyte/macrophage-mediated inflammatory responses has not been defined.

    Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma

    Hebing Zhou, Jinqing Li, Yuan Jian, Tingting Chen, Haiteng Deng, Juan Zhang, Hui Zeng, Zhijuan Shan, Wenming Chen

    The anti-tumor potential of arsenic trioxide (ATO) and recombinant mutant human TRAIL (rmhTRAIL) has been confirmed in various kinds of tumors. However, the effects and mechanism of the two drugs in combination in multiple myeloma (MM) have not been established. In this study, we evaluated the proliferation inhibition and apoptosis induction effects of ATO and rmhTRAIL as single agents and in combination on the MM cell lines RPMI8226 and U266. Then, we used high-performance liquid chromatography and mass spectrometry to find differentially expressed proteins before and after drug treatment and to analyze the mechanism underlying the effect of ATO and rmhTRAIL on MM cells.

    Bleeding the laboratory mouse: Not all methods are equal
    Jonathan Hoggatt, Amber F. Hoggatt, Tiffany A. Tate, Jeffrey Fortman, Louis M. Pelus

    The laboratory mouse is the model most frequently used in hematologic studies and assessment of blood parameters across a broad range of disciplines. Often, analysis of blood occurs in a nonterminal manner. However, the small body size of the mouse limits collection based on volume, frequency, and accessible sites. Commonly used sites in the mouse include the retro-orbital sinus, facial vein, tail vein, saphenous vein, and heart. The method of blood acquisition varies considerably across laboratories and is often not reported in detail.

    Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta

    Katia Mareschi, Sara Castiglia, Fiorella Sanavio, Deborah Rustichelli, Michela Muraro, Davide Defedele, Massimiliano Bergallo, Franca Fagioli

    Mesenchymal stromal cells (MSCs) are a promising tool in cell therapies because of their multipotent, bystander, and immunomodulatory properties. Although bone marrow represents the main source of MSCs, there remains a need to identify a stem cell source that is safe and easily accessible and yields large numbers of cells without provoking debates over ethics. In this study, MSCs isolated from amniotic fluid and placenta were compared with bone marrow MSCs. Their immunomodulatory properties were studied in total activated T cells (peripheral blood mononuclear cells) stimulated with phytohemagglutinin (PHA-PBMCs).

    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside this Issue: November and December

    Posted By Connections Editor, Wednesday, December 16, 2015



    Newly identified mutations contributing to leukemogenesis and therapy resistance in AML
    See Sykes et al., pages 989

    Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Unfortunately, even with aggressive treatment, including high-dose chemotherapy and bone marrow transplantation, most patients relapse and develop resistance to anti-leukemic therapies, resulting in 5-year overall survival rates between 30% and 40%. Increasing evidence supports a model for leukemia evolution whereby mutations accumulate in functionally normal hematopoietic stem cells during a prolonged “preleukemic” phase. Recent advances in whole-genome sequencing and global genomic approaches have provided a long list of newly identified mutations. However, even with these advances, how these molecular abnormalities contribute to the etiology, pathogenesis, and therapeutic responses of AML remains largely unknown. The International Society of Experimental Hematology invited Dr. Ross L. Levine and Dr. Ravindra Majeti, two authorities on AML, to conduct a webinar (available online at presenting their most recent research on this topic. In this perspective, Sykes et al. summarize the key points discussed in both presentations, which centered on the most recent published data concerning the pathogenesis of AML, including, but not limited to, clonal evolution, newly identified mutations in AML patients, and mutational cooperativity. In addition, they discuss the clinical and basic research implications of their work, as well as novel therapies that are currently emerging in AML treatment.


    Multiple roads to genomic instability in Fanconi anemia
    See Abdul-Sater et al. pages 1031

    Inherited mutations within FANCA or other FA genes cause Fanconi anemia (FA), a bone marrow failure syndrome associated with myelodysplasia (MDS) and acute myeloid leukemia (AML). Acquired FA mutations drive AML in patients without FA. The FA pathway orchestrates both interphase DNA repair and mitosis; thus, FA mutations may unleash genomic instability via multiple mechanisms. However, the in vivo impact of interphase and mitotic errors on FA−/− hematopoiesis is unknown. To address this issue, Abdul-Sater et al. employed in this study a battery of quantitative assays and discovered increased frequency of abnormal mitoses during in vivo hematopoiesis in non-leukemic FANCA−/− patients and Fancc−/− mice, suggesting that these mitotic errors may ultimately cause leukemia. Mechanistically, live FANCA−/− cells failed to efficiently assemble mitotic spindles. Superresolution microscopy revealed that FANCA shuttles from centrioles to microtubule- attachment sites at the centrosome periphery in early mitosis, possibly to fine-tune microtubule nucleation.
    In accordance with FA genes acting as mitotic housekeepers, loss of FANCA or FANCC rendered cells hypersensitive to antimitotic chemotherapeutics. Importantly, the authors illustrate that functionally different chemotherapeutics selectively damage FA−/− cells through distinct mechanisms. Although crosslinking drugs shatter DNA and activate the G2/M cell cycle checkpoint, low-dose antimitotic chemotherapy amplifies chromosome segregation errors. Accordingly, loss of FA signaling promotes genomic instability through complementary interphase and mitotic defects. Together, these findings not only provide insights into the complex mechanisms of genomic instability resulting from loss of the FANCA tumor suppressor, but also suggest that precision medicine therapeutics targeting erroneous mitosis may selectively kill FANCA−/− leukemia and other cancers.


    VEGF may not be the most suitable target for anti-angiogenic therapy in primary myelofibrosis
    See Dragoni et al., pages 1019

    Increased angiogenesis is a major histopathologic feature of both bone marrow and spleen of patients with primary myelofibrosis (PMF). This has prompted the design of therapeutic protocols based on the use of anti-angiogenic drugs directed mainly against vascular endothelial growth factor (VEGF), the major regulator of such a process. However, despite the strong rationale for the use of anti-VEGF treatments, these trials have resulted in poor outcomes. In the recent past, it has been proposed that circulating endothelial progenitor cells have a role in angiogenesis in different diseases, including PMF. Dragoni et al. report that PMF patient-derived endothelial colony-forming cells, the only bona fide endothelial progenitor cells described so far, mount a defective proangiogenic response to VEGF in vitro, assessed in terms of Ca2+ oscillations, proliferation, and tubulogenesis. Importantly, this reported alteration in VEGF-mediated calcium flux in these endothelial colony-forming cells was previously unrecognized. These results, in addition to the previous report from the same group of an increased frequency of these cells in the peripheral blood of PMF patients, open new perspectives on the potential role of circulating endothelial progenitor cells in the pathogenesis of PMF. In particular, these data shed new light on the failure of anti-VEGF therapy in PMF patients and represent valuable information for the design and development of new anti-angiogenic drugs for the cure of this disease.


    Innate and adaptive immune response: Help for curing CML?
    See Caocci et al., pages 1015
    Withdrawal of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML) continues to be a much debated issue, and the search for clinical and/or biological patterns predictive of stable molecular remission (MR) and, perhaps, even definitive recovery is still underway. In a previous article, this group reported that homozygosity for killer cell immunoglobin-like receptor (KIR) A haplotype was significantly associated with achievement of deep MR. In this article, Caocci et al. report that after discontinuation of TKIs, MR was significantly higher in patients homozygous for KIR A haplotype and/or carrying specific combinations of KIRs and their HLA class I ligands. Although the study cohort is quite small and a bit heterogeneous, this article provides interesting novel findings on a hot topic in current CML treatment and suggests that natural killer cells and their KIRs cooperate with TKIs in the cure of CML.
    There are many reasons why both physicians and their patients prefer to stop therapy. Some worth mentioning are the high cost, adverse events, poor compliance, the desire for pregnancy, and treatment-related poor quality of life. Ongoing clinical trials investigating TKI discontinuation should soon release more details on the safety of stopping treatment and the ideal candidates for this option. Meanwhile, on the basis of this and other studies, the important function of both innate and adaptive immune responses in controlling CML should be given attention. Further appreciation of immune regulation is a fundamental step toward improved treatment approaches and the development of anti-inhibitory KIR antibodies or vaccination strategies.





    Reduced dose of cyclophosphamide post-HLA haploidentical peripheral blood stem cell transplantation as an option for high-risk leukemia and MDS patients
    See Nakamae et al., pages 921–929

    Nonmyeloablated T-cell–replete HLA haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide (PT/Cy) has shown encouraging outcomes with low transplantation-related mortality. High-dose Cy is capable of controlling graft versus host disease (GVHD) and preventing graft rejection; however, the high relapse rate remains a major issue of concern, particularly with high-risk hematological malignancies. In this prospective pilot study, Nakamae et al. investigate two reduced dosages of PT/Cy for patients with a poor prognosis, refractory leukemia, or myelodysplastic syndrome. The authors report a trend toward a lower incidence of severe acute GVHD at day 100 in the “25 mg/kg × 2 doses of PT/Cy” group compared with the “25 mg/kg of PT/Cy” group. Although they use peripheral blood as a stem cell source for all patients, the cumulative incidence of chronic GVHD was very low in both groups. BK virus hemorrhagic cystitis occurred more frequently in the double-dose PT/Cy group, particularly when busulfan was used for conditioning. The probability of overall survival at 1 year in the double dose group was better than that in the single dose group despite the absence of statistical significance. Overall, these results suggest that HLA haploidentical T-cell–replete peripheral blood stem cell transplantation with 25 mg/kg × 2 doses of PT/Cy might be a feasible option for high-risk leukemia and MDS patients. It thus might be worthwhile to compare the efficacy of a double dose of 25 mg/kg PT/Cy with the original PT/Cy double dose of 50 mg/kg in a large prospective study.


    Osteoblast stimulating factor-5 (OSF-5); a novel tuner in B lymphopoiesis
    See Fujita et al., pages 963–973

    B lymphocytes are developed from hematopoietic stem cells (HSC) in their specialized microenvironment. In contrast to the recent progress in understanding the HSC niche, the mechanisms regulating the B lymphopoietic niche have remained unclear. To shed light on this issue, Fujita et al. identify several molecules secreted by the B lymphopoietic niche using signal sequence trap. First, the authors examined the proteins produced by MS5 stromal cells, which are B lymphopoiesis supportive cells commonly used in models of in vitro B lymphopoiesis. They identified pleiotrophin, placental proliferin-2, and osteoblast stimulating factor-5 (OSF-5). On the basis of experiments with transgenic mice and in vitro studies, they found that a secreted variant of OSF-5 inhibits proliferation at the pre–B cell stage. Furthermore, the authors show that human mesenchymal cells also express OSF-5 and, as in mice, this molecule suppresses the proliferation of human pre–B cells. These results identify OSF-5 as a new negative regulator of B lymphopoiesis and provide a framework to identify molecules that can be used to speed the regeneration of the humoral immune system after chemotherapy, and potentially suggesting ways to inhibit the growth of B lineage malignancies.


    New biomarkers of AML dynamics
    See Tzoran et al., pages 936–943

    Acute myeloid leukemia (AML) is characterized by rapid growth of leukemic blasts. Cell exposure to chemo- or radiotherapy increases the shedding into the blood circulation of extracellular vesicles (EVs), which express antigens reflecting their cellular origin. Despite normalization of blood counts, AML patients in remission still harbor leukemic burden. This fact emphasizes the need to develop diagnostic tools capable of identifying minimal residual disease (MRD). The current study by Tzoran et al. explores the role of circulating EVs as potential biomarkers of AML activity and predictors of thrombogenicity in patients who are reported to be at increased risk for thrombotic events. The authors demonstrate that circulating EVs of AML patients express leukemic blast membrane proteins, with their levels significantly varying at diagnosis, nadir, and remission, thus reflecting the disease dynamics. Blast EV counts were found to be higher in patients at diagnosis compared with healthy controls. In remission, a statistically significant correlation between the percentage of CD117-labelled EVs in the peripheral blood and the amount of CD117-positive blasts in the bone marrow was revealed. Moreover, blast EV levels at remission were significantly lower in patients who were alive at 3 years of follow-up compared with those who succumbed to the disease, indicating the high predictive value of this biomarker. Additionally, EV procoagulant activity was increased in patients compared with controls and induced high endothelial cell thrombogenicity. This study provides a platform for the use of EVs as potential biomarkers of minimal residual disease and the procoagulant state in AML patients.


    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside this Issue: September and October

    Posted By Connections Editor, Friday, November 6, 2015
    Updated: Thursday, November 5, 2015


    A new tool to identify the molecular and functional properties of individual stem cells at a single-cell resolution
    Schulte et al., pages 803–811.


    The recent discovery of significant heterogeneity in normal and malignant stem cell populations has driven the development of numerous tools to try and identify, at single-cell resolution, what the molecular and functional properties are of individual stem cells. Many groups have identified populations of hematopoietic stem cells that are based on a binary positive/negative gate and do not take into account the differing levels of proteins on the cell surface (i.e., how positive is a cell for marker X). To consider this, in this manuscript, Schulte et al. combine flow-cytometric index sorting (which quantifies the exact fluorescence of each cell surface marker form each single cell) with single-cell functional assays to determine whether or not different levels of cell surface molecules can enrich or deplete for functional activity. This technique is particularly useful when cell number is limited and can assess multiple marker intensities simultaneously in a single experiment. The technique has been already been usefully applied to uncover the molecular program of functional hematopoietic stem cells (HSCs; Wilson et al., Cell Stem Cell 2015) and can be applied to any cell-biological system with a defined single cell functional assay.

    How the experimental setup of serial transplantations largely influences the interpretation of long-term HSC performance
    Rundberg Nilsson et al., pages 812–817.

    To study HSC self-renewal and longevity, serial transplantation has been considered the gold standard for many years. However, discrepancies in experimental procedures are widespread, including the choice to either transplant whole bone marrow (wBM) or fluorescence-activated cell sorting (FACS)-purified HSCs into secondary hosts. In this study, Rundberg Nilsson et al. show that this choice of experimental procedure significantly influences the readout following transplantation. The authors show that donor-derived HSCs can distribute highly unevenly among bones of the conditioned host, leading to serial transplantation of nonrepresentative HSC chimerism levels if wBM is isolated and transplanted from only one or a few bones. Moreover, by comparing mature donor cell output from transplanted wBM cells as opposed to FACS-purified HSCs, they found differences suggestive of cotransplantation of long-lived lymphoid progenitors and/or mature cells together with HSCs in the wBM, which could severely affect the interpretation of ongoing HSC activity. Furthermore, transplantation of different frequencies of HSCs using wBM transplantation between groups/recipients not only impeded the evaluation of the HSCs on a per cell basis, but also obscured the distinction between effects generated during the primary transplantation and those presenting during the secondary transplantation. Based on these data, the authors recommend serial transplantation of highly purified HSC populations using flow cytometry markers as opposed to unfractionated wBM. A standard experimental setup, such as the one suggested in this study, is highly important for the research community, both to aid comparison of results generated from different research groups and for optimal evaluation of HSC performance.

    Targeting autophagy to promote differentiation in myeloid leukemia
    Orfali et al., pages 781–793.

    Acute myeloid leukemia (AML) affects predominantly an elderly population, who tend to tolerate intensive chemotherapy poorly. Differentiation therapy, a pharmacologic override of the differentiation block observed in this condition, is an attractive and potentially minimally toxic strategy. The use of all-trans-retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL) is the defining example of success in this field and a model for the study of differentiation pathways in myeloid cells. Recently published literature reports that ATRA treatment of APL cells induces autophagy, a lysosomal-dependent protein recycling pathway with defined roles in mammalian cell differentiation.
    In this study, Orfali et al. investigate a functional role for autophagy in leukemic cell differentiation. The authors initially confirm the induction of autophagy by ATRA in
    an APL cell line and in primary APL tissue cultured ex vivo. They proceed to demonstrate that autophagy blockade, using either pharmacologic agents (Chloroquine/3-methyladenine) or genetic inhibition of the critical autophagy regulator ATG7, impedes ATRA-mediated APL cell differentiation. Conversely, in an exciting experiment, the investigators show that promoting autophagy with the use of lithium chloride can enhance the differentiating effects of ATRA in AML cells previously resistant to differentiation.

    In a time when the molecular heterogeneity of AML is increasingly understood, this work considers the endpoint at which these aberrancies converge: the differentiation block. If autophagy is of functional importance in leukemic cell differentiation, it is possible that defective autophagy could contribute to their malignant phenotype. Importantly, autophagy induction with readily available compounds may overcome ATRA-resistance in APL and potentiate the differentiation of non-APL leukemic subtypes.

    Using cellular reprogramming to make blood
    Singbrant et al., pages 756–759.

    The current use of human HSCs to treat blood disorders is hampered by the need to find human leukocyte antigen (HLA)-matched donors and to obtain sufficient numbers of long-term engraftable HSCs. Despite the efforts of many researches, ex vivo expansion of HSCs to improve hematopoietic reconstitution and engraftment potential has been largely unsuccessful owing to the inability to generate sufficient HSC numbers and to excessive differentiation of the starting cell population. In search for an unlimited source of autologous HSCs, novel approaches, such as the reprogramming of somatic or pluripotent cells lines to HSCs, are now being pursued. Induced HSCs (iHSCs) hold much potential for regenerative medicine and, in the near future, could benefit patients through disease modeling and drug screening. The International Society of Experimental Hematology invited Drs. George Q. Daley and Derrick Rossi, two leaders in the field of cellular reprogramming, to present a webinar ith their most recent research on this topic. In this perspective, Singbrant et al. summarize the webinar (available online at and discuss the state of the field of hematopoietic specification.


    Gene correction of a chronic granulomatous disease-causing mutation in iPS cells
    Flynn et al., pages 838–848.

    Chronic granulomatous disease (CGD) is a lifelong affliction causing serious morbidity and potential mortality, even in the present era of potent antimicrobials. Currently, the only curative treatment option involves allogenic bone marrow transplantation. However, a preferred option to avoid the inherent risks associated with this treatment, could be transplantation with genetically-modified, patient-derived cells (either from induced pluripotent stem [iPS] cell or the patient's bone marrow) would theoretically improve outcomes dramatically. To that end, in this study, Flynn et al. use the Cas9–clustered regularly interspaced short palindromic repeats (CRISPR) system to efficiently gene correct a CGD-causing point mutation in a patient-derived iPS cell line. This in situ modification of a single-point mutation within an intron of the main disease causing gene, CYBB, results in the correction of a splicing defect and restoration of the oxidative burst in macrophages derived from the iPS cells, a key antimicrobial response that is compromised in CGD sufferers. This work lays the foundation for future genetically clean (“footprintless”) gene therapy approaches to this, and other, life-threatening genetic diseases.

    Encouraging advances in treating and curing globin disorders
    Blobel et al., pages 821–837.

    Throughout the era of molecular medicine, lessons learned from the globin gene disorders have led the way forward for research of many human genetic diseases. The pathway from understanding a human disease to developing an appropriate treatment or cure often takes decades. Thalassemia and sickle cell disease, which cause serious illness in millions of individuals worldwide, were arguably the first human genetic diseases to be understood at the molecular and cellular level, yet in more than 50 years of research, this increasingly detailed understanding has had only a modest impact on clinical treatment. However, recent, significant advances in our understanding of the developmental regulation of globin gene expression and in the technology for safely manipulating hematopoietic stem cells engender optimism that improved management for these disorders may be on the near horizon. Altering the normal developmental pattern of globin gene expression could be the most efficient way to treat the thalassemias, and over the past two decades, specific new pathways that regulate developmental switching have been identified, suggesting new ways to manipulate the activity of individual globin genes. Similarly, the promise of gene therapy to treat thalassemia, after three decades of meticulous study, has been achieved by lentiviral transduction of blood stem cells in affected patients. Genome editing of such cells may also soon be a reality. These advances, as well as many others, were presented at the 19th biennial Hemoglobin Switching Conference, held this past September in Oxford, United Kingdom, by the 160 participants who traveled from around the world to participate in this unique conference. This review by Blobel et al. highlights many of the most recent advances that were presented during the three days, and highlights why this meeting has become one of the most important international conferences examining the developmental biology, molecular genetics, cell biology, and epigenetics of human disease.

    Interferon α promotes hematopoietic stem and progenitor division in humans
    King et al., pages 912–918.

    Named for their ability to interfere with viral transmission, interferons suppress the growth and survival of many cell types. Surprisingly, however, hematopoietic stem cells (HSCs) are activated to divide by the Type I interferon, interferon α, in murine in vivo studies. Similar effects have also been seen in response to Type II interferon. King et al. postulate in this study that interferon-mediated activation of HSC division could be a primitive mechanism for generating innate immune responses. To evaluate the effects of interferon α on human HSCs in vivo, serial bone marrow (BM) samples from patients with polycythemia vera or essential thrombocytosis were collected before and during treatment with pegylated interferon α. While the absolute number of CD34+CD38− hematopoietic stem and progenitor cells (HSPCs) did not change, the percentage of CD34+ cells undergoing cell division increased in most patients treated with pegylated interferon α. Furthermore, colony formation of whole BM cells in methylcellulose increased, indicative of enhanced differentiation. These findings were present even in patients with low or undetectable JAK2-mutant allele burden, suggesting that they reflect the activity of wild-type Jak2 in HSPCs. In contrast, patients treated with hydroxyurea, an antimetabolite, showed decreased cell division and decreased colony formation. This unique in vivo longitudinal study demonstrates for the first time in a human setting that interferon α can be used to promote division of quiescent HSPCs; this application may promote polyclonal hematopoiesis in patients with myeloproliferative neoplasms and improve chemosensitivity of hematologic malignancies.

    MicroRNA-223 is a promoter of lineage commitment and differentiation and a modulator in AML
    Gentner et al., pages 858–868.

    Although the effect of miR-223 on granulopoiesis was recognized over 10 years ago, its role in hematopoietic stem and progenitor cells (HSCPs) and in acute myeloid leukemia (AML) is still not completely understood. In this study, Gentner et al. explore the role of miR-223 in various murine AML models and human CD34+ cells. Considering that high miR-223 levels were associated with favorable prognosis and that the expression of miR-223 was low in leukemia-initiating cell (LIC) fractions of AML patients, it is surprising that genetic depletion of miR-223 decreased the LIC frequency in an AML mouse model, but was not mandatory for rapid onset AML, indicating only a minor role in AML development. This correlates with their observations in CD34+ cells, where miR-223 fine tunes myeloid progenitor cells with respect to myeloerythroid differentiation and expansion. The findings of Gentner et al. close the gap between in vitro findings and the actual function of miR-223 in vivo as a regulator of the expansion/differentiation equilibrium in HSPCs cells and in AML, highlighting its role as rheostat and not on-or-off switch in granulopoiesis.

    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside Experimental Hematology: July 2015

    Posted By Connections Editor, Monday, August 31, 2015
    Updated: Tuesday, August 25, 2015

    Current state of attempts to improve the efficacy of cord blood transplantation using stem cell-based technologies
    Pineault et al., pages 498–513.

    It is increasingly difficult to find suitablematched donors for hematopoietic stem cell transplant in developed countries due to a variety of factors including an aging population and decreased birth rates. Cord blood (CB) stem cells now represent an important source of hematopoietic stem and progenitor cells (HSPC) for patients with no suitable unrelated donor. However, the major limitation of CB transplantation is the limited number of total nucleated cells and HSPCs banked per unit. Transplantation of two partially matched units can overcome this shortcoming but fails to accelerate engraftment. Ex vivo expansion of CB HSPCs has made significant headway in recent years; accelerated neutrophil recovery, improved platelet engraftment, and superior therapeutic outcomes have now been reported in several clinical trials. In this review, Pineault et al. describe some of the most significant advances made toward improving CB engraftment through stem cell engineering. This review focuses on the development of culture strategies designed to expand human HSPCs ex vivo and the enhancement of engraftment through improved homing. The contributions of coculture, cytokines, developmental-related genes, and small molecules to advancements in CB transplantation are discussed. The major findings of studies that defined the short- and long-term engraftment properties of expanded HSPCs are presented in a series of supporting tables. Finally, the results and principal lessons learned from clinical trials conducted with expanded CB HSPCs are presented along with future perspectives of interest. In summary, this review provides experienced or entry-level readers of all fields with an up-to-date assessment of both fundamental and translational research on stem cell–based technologies developed to improve CB transplantation outcomes.


    A widely applicable Kit and Sca-1 independent identification of hematopoietic stem cells
    Vazquez et al., pages 578–585.

    Hematopoietic stem cell (HSC) transplantation holds promise in many disease settings, including cancers, bone marrow failure, and autoimmune disease. The surface markers Kit and Sca-1 are commonly used to isolate HSCs in mice. However, some strains of mice, including the NOD mouse that is used to study autoimmune diabetes, do not express Sca-1 on their hematopoietic progenitors. Similarly, Kit is dynamically regulated in response to bone marrow injury and cannot be used to identify HSC following irradiation. It is therefore important to have an alternative identification approach to Kit and Sca-1 staining that is both simple and efficient. In this manuscript, Vazquez et al. found that antibodies to CD201 and CD27 enable HSC identification across a wide variety of mouse strains, and the expression of these markers is maintained following irradiation. These markers will facilitate the application of HSC transplantation to disease models such as the NOD mouse, as well as in settings where Kit and Sca-1 are dynamically regulated.


    Proapoptotic function of hyperactivated AKT1 in AML
    Tang et al., pages 554–564.

    Elevated levels of phosphorylated AKT1 are frequently seen in leukemic blast cells. However, reoccurring mutations in the Akt1 gene are absent in patients with acute myeloid leukemia (AML), raising the question whether permanent AKT1 activation is incompatible with leukemogenesis. Previous reports have indicated that AKT1 activation leads to increased levels of reactive oxygen species (ROS), triggering apoptosis. Whether this is true in cells coexpressing other genetic events in leukemia is not known. To elucidate whether AKT1 causes apoptosis when coexpressed with additional oncogenes seen in AML, in this study, Tang et al. coexpressed hyperactivated AKT1 with STAT5, FLT3-ITD, or antiapoptotic Bcl-2 in hematopoietic progenitors. Hyperactivation of AKT1 was incompatible with both STAT5- and FLT3-ITD-driven proliferation, and triggered cell cycle block and apoptosis. Moreover, transplantable cells of Bcl-2 transgenic mice were impaired in their engraftment ability when expressing hyperactivated AKT1. Cells expressing hyperactivated AKT1 displayed higher levels of ROS, which could be counteracted by addition of the antioxidant N-acetyl-L-cysteine (NAC). These results indicate that constitutive AKT1 activity is incompatible with growth- and survival-promoting ability of other activated genes in AML. Because the harmful effects of hyperactivated AKT1 on hematopoietic cells was linked to an improper balance of ROS, this could be one reason why activating mutations of Akt1 are absent in AML. Considering that activating mutations of FLT3-ITD and other signaling proteins in leukemia activate the PI3K/AKT pathway, future drug development to enhance AKT1 activity could lead to novel ways of eradicating leukemic cells.


    LSD-1 inhibitor RN-1 induces γ-globin expression in a sickle mouse model
    Rivers et al., pages 546–553.

    Increased fetal hemoglobin production is associated with decreased symptoms and increased life span in patients with sickle cell disease (SCD). Lysine demethylase-1 (LSD1), an enzyme that removes methyl groups from mono- and dimethylated lysine 4 amino acids of histone H3, is a repressor of γ-globin gene expression. LSD1 is also highly overexpressed in many cancers and is a target for anticancer drug therapies. Tranylcypromine (TCP), an FDA-approved LSD-1 inhibitor, increases γ-globin in cultured human erythroid progenitors and induces differentiation of AML cell lines in combination with retinoic acid. Using a novel approach, in this manuscript, Rivers et al. identified RN-1 as a biologically active LSD-1 inhibitor that induced differentiation of the U937 AML cell line with increased potency compared to tranylcypromine. The authors then performed in vivo studies in the SCD mouse model to test the ability of this drug to induce γ-globin messenger RNA. RN-1 treatment of SCD mice induced γ-globin messenger RNA, F cells, and F retics to higher levels than either TCP or hydroxyurea, and its effect was comparable to decitabine, currently in clinical trials for SCD. Because the level of γ-globin induction in the SCD mouse model is low, the authors intend to perform additional studies in the baboon nonhuman primate model that has reproducibly facilitated clinical translation of novel fetal hemoglobin–inducing therapies for SCD.

    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside this Issue: May and June

    Posted By Connections Editor, Wednesday, July 1, 2015
    Updated: Monday, June 29, 2015


    RPL11 and RDH11 induce erythroid proliferation without Epo
    Kummalue et al., pages 414–423.

    Understanding the essential genes involved in erythropoiesis would help to clarify the pathobiology and improve the treatment of patients with anemia resulting from the abnormal production of erythroid cells. In this study, using lentivirally transduced UT-7/Epo erythroleukemic cells, Kummalue et al. identified 2 pivotal genes, i.e., ribosomal protein L11 (RPL11) and retinol dehydrogenase 11 (RDH11). Both RPL11- and RDH11-transduced cells could proliferate without erythropoietin with RPL11-transduced cells showing high proliferation rate. The antiapoptotic protein BCL-XL was highly detected in both transduced cells, and STAT5 signaling pathway was activated by Lyn and CREB phosphorylation. Moreover, cell-cycle profiles of both transduced cells revealed G0/G1 prolongation and low percentages of apoptosis. Interestingly, the hemoglobins in both transduced cells were switched from adult to fetal. These findings provide important insights into the mechanisms underlying induction of erythroid proliferation and may lead to improved therapeutic approaches for patients with diseases such as myelodysplastic syndrome, Diamond–Blackfan anemia, and acute erythroleukemia, which are still too difficult to manage, and specific treatments remain to be developed.


    Components of the microRNA-induced silencing complex in red blood cells
    Azzouzi et al., pages 382–392.

    Erythropoietic cells extrude their nucleus but retain their ability to respond to stimuli by regulating protein translation, a process that can be regulated by microRNAs (miRNAs). In this study, Azzousi et al. identified both the miRNA and the protein components forming the miRNA-inducing silencing complex in circulating red blood cells (RBCs) by using a combination of deep sequencing of small RNA species and endogenous Argonaute 2-immunoprecipitation followed by mass spectrometry. Almost 200 different miRNAs and 26 different proteins that interact with Argonaute 2 were identified, giving a comprehensive overview of the miRNA-inducing silencing complex components in circulating RBCs. MicroRNA-451a was found to be the dominant species, with over 60% of total reads, and was shown to interact with its known target, 14-3-3zeta, in an Argonaute2-dependent manner. This study points at the possibility of miRNAs in circulating RBCs as biologically active molecules, and provides a starting point for in depth analysis of miRNA-regulated processes in these enucleated cells. This study not only gives novel insight into erythrocyte homeostasis, but will lead to a better understanding of erythroid diseases as well.


    TXNIP, a novel player in erythroid differentiation
    Gasiorek et al., pages 393–403.

    Besides a well-characterized role in redox control and cell cycle, there are only a few reports that have implicated Thioredoxin-interacting protein (TXNIP) in the function of hematopoietic cells, namely natural killer, dendritic, and hematopoietic stem cells. In this study, Gasiorek et al. present the first report of a role for TXNIP in terminal erythropoiesis. TXNIP was robustly upregulated upon induction of erythroid differentiation in two different cellular models. Furthermore, inhibiting the MAP kinases p38 and JNK induced the levels of TXNIP. Flow cytometry experiments revealed that, in vivo, TXNIP knockout mice displayed impaired splenic erythropoiesis, characterized by a partial block between basophilic and late basophilic/polychromatic erythroblasts. It will be of interest to identify the pathways targeted by TXNIP at this transition step. In this report, the authors suggest that one of the mechanisms may be the effect of TXNIP on cellular iron levels, since they observed increased iron uptake upon TXNIP overexpression. This study introduces TXNIP as a new player in the field of erythropoiesis and opens the door to research on its implication in an important process for red blood cell differentiation, namely iron homeostasis.


    Potential side effects of dasatanib on host immunity
    Oksvold et al., pages 352–363.

    Dasatinib is a widely used broad-spectrum tyrosine kinase inhibitor with potential for its clinical application to be expanded beyond chronic myeloid leukemia. Recently, this group found that dasatinib significantly reduced B cell numbers when used as a treatment for myeloproliferative disease in c-Cbl RING finger mutant mice. These findings highlighted the lack of studies investigating the effects of dasatinib on B cells from wild-type mice and humans. In this study, Oksvold et al. show that dasatinib has an inhibitory impact on human and mouse B-lymphocytes. They found that dasatinib markedly reduced the number of human CD19+ peripheral B cells in culture through the induction of apoptosis, yet it had no impact on T cell viability despite broad inhibition of early signaling events in both B and T cells. Sensitivity to dasatinib was also shown in human pre-B cells in vitro and in mouse pre-B cells in vivo. Furthermore, dasatinib targeted actively cycling mouse B-lineage cells in the spleen and caused a marked loss of thymocytes. In contrast, no impact was seen in myeloid lineage cells or hematopoietic progenitors. These findings are important and have potential implications for infection prevention strategies for patients receiving dasatinib. In this regard, Rodriguez et al. reported in August 2012 in Leukemia & Lymphoma a single institute cohort study in which 69 patients received dasatinib treatment for chronic myeloid leukemia or Ph+ ALL. Bacteria were the most common offending microorganisms and pneumonia was the most common type of infection associated with dasatinib. A more recent study published by Chang et al. last August in the International Journal of Infectious Diseases reported Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment. Both studies have raised attention to the possible effects of dasatinib on cellular immunity. Hence, studies such as the one performed by Oksvold et al. are important to further our understanding of the potential effects of this drug on cellular immunity, especially in view of the fact that dasatinib is increasingly used as a treatment modality for hematopoietic malignancies. Overall, these results underline the importance of thorough investigation of the effects of kinase inhibitors on immunity and suggest that dasatinib may adversely impact patients' immune responses, especially those receiving long-term treatment.



    Autophagy regulates platelet production
    Cao et al., pages 488–494.

    Megakaryopoiesis, megakaryocyte differentiation, and thrombopoiesis are regulated at multiple stages during hematopoiesis. These involve successive lineage commitment followed by polyploidization, maturation, and development of an extensive internal demarcation membrane system, leading to the release of platelets in circulation. The cellular mechanisms by which megakaryocytes derive from their progenitors and megakaryocytes differentiate into platelets are not fully understood. In this paper, Cao et al. set out to study the role of autophagy, a metabolic process essential in homeostasis and cellular remodeling, on megakaryopoiesis and platelet function. Using an autophagy-related gene (Atg7) hematopoietic conditional knockout mouse model, they report that loss of autophagy caused mitochondrial and cell cycle dysfunction, impeding megakaryopoiesis and megakaryocyte differentiation, as well as thrombopoiesis. In addition, abnormal platelets with larger size and smaller number were produced in peripheral blood, ultimately leading to severely impaired platelet production and failed hemostasis. These data suggest that autophagy is essential for megakaryopoiesis, megakaryocyte differentiation, thrombopoiesis, and platelet production. Given these results, autophagy may serve as a suitable target for megakaryocyte/platelet disorders in clinical conditions.


    You can count (on) this: Chimerism analysis going digital
    Stahl et al., pages 462–468.

    Hematopoietic chimerism, i.e., the ratio between donor and recipient blood cells after allogeneic stem cell transplantation, is a crucial diagnostic parameter in the posttransplant period. To assess chimerism, donor-/patient-specific genetic markers in polymorphic genome regions are investigated. The current gold standard of chimerism analysis employs polymerase chain reaction (PCR)-based amplification of repetitive DNA sequences, such as short-tandem repeats (STRs), and quantification of donor-/recipient-specific PCR products by capillary electrophoresis. This method is robust, but its detection limit of approximately 1% is unsatisfactory. Newer techniques measuring the presence of insertion/deletion polymorphisms by real-time quantitative PCR (qPCR) are much more sensitive, but are hampered by comparatively low accuracy in the state of mixed chimerism (10%–90% donor cells). To overcome the inherent limitations of classical qPCR in chimerism analysis, Stahl et al. propose in this study the use of digital PCR. Digital PCR (dPCR) is based on the compartmentalization of single DNA molecules, allowing the parallel but separate amplification of large numbers of individual target sequences. Digital PCR represents an end-point analysis and is, in contrast to qPCR, not influenced by the efficiency of individual PCR reactions. Taking advantage thereof, the authors simultaneously quantified both donor- and patient-specific alleles in single tubes (duplex). They show that dPCR combines the excellent sensitivity of qPCR with the high accuracy and reproducibility of STR-PCR. Since dPCR is easy to perform and interpret, it has the potential to become the new standard in chimerism analysis. To achieve this, a broad panel of assays covering multiple insertion/deletion polymorphisms will be required.


    Transferrin receptor 1 (TfR1) signals erythron iron need
    Keel et al., pages 469–478.

    When there is systemic iron deficiency, marrow erythroid cells upregulate TfR1 to assure that residual transferrin-bound iron is preferentially imported for hemoglobin synthesis and red cell production. Similarly, TfR1 is upregulated whenever erythropoiesis expands and additional iron is needed. In both settings, the liver also synthesizes less hepcidin, which acts by binding the iron export protein, ferroportin, leading to its degradation. This inhibits dietary iron absorption and macrophage iron recycling so that iron is more rapidly absorbed form the gastrointestinal tract, more rapidly released from macrophages, and thus more available to the erythron. How an erythroid precursor in the bone marrow communicates its iron need to hepatocytes is a major unresolved question in the field of iron homeostasis. In this manuscript, Keel et al. ask whether TfR1, besides assuring adequate marrow iron import, is also responsible for alerting the liver to suppress hepcidin. The authors studied a unique pure red cell aplasia patient with erythroid arrest at the proerythroblast stage, presenting with excess marrow proerythroblasts (highly expressing TfR1) but no hemoglobinized cells. The patient's serum hepcidin was low, while pure red cell aplasia patients who lack all erythroid precursors had high serum hepcidins, suggesting that TfR1 is a proximal mediator of the erythroid regulator of hepcidin expression. Their additional studies in mice genetically engineered to be deficient in TfR1 further imply that TfR1 either regulates the release of a yet-to-be-defined mediator of hepcidin expression or regulates at the post transcriptional level erythroferrone, a tumor necrosis factor α superfamily member that regulates hepcidin production after phlebotomy and after erythropoietin administration. The data presented in this study also help explain prior findings from ferrokinetic studies in humans, studies in hypotransferrinemic mice, and studies in mice lacking signal transducer and activator of transcription 5 in hematopoietic cells. The data also imply that iron homeostasis and red cell production are intricately connected through multiple, and likely independent, links.

    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside this Issue: March and April 2015

    Posted By Connections Editor, Friday, May 1, 2015
    Updated: Wednesday, April 29, 2015

    March 2015

    Mutant forms of c-Cbl and FLT3 cooperate to enhance myeloid leukemia development
    Taylor et al., pages 191–206.

    Fms-like tyrosine kinase (FLT) 3 mutations, especially internal tandem duplications (ITDs), are prevalent in acute myeloid leukemia (AML). Currently, there is conjecture over the negative regulation of the aberrantly localized FLT3-ITD protein, particularly in regard to E3 ubiquitin ligases such as c-Cbl. A greater understanding of these pathways could provide insight into novel targets for the treatment of AML. Hence, in this study, Taylor et al. investigated the role of c-Cbl in the regulation of the FLT3-ITD protein by generating of a double-mutant mouse containing both a FLT3-ITD and a c-Cbl RING finger domain mutation. The combination of the two mutations severely affected embryonic development, necessitating the generation of mice repopulated with E.14 fetal liver cells. These double-mutant transplanted mice developed an aggressive myeloid leukemia, with a phenotype markedly more severe than mice with either of the single mutations. The disease was characterized by a large increase in blast and myeloid cells and short survival. Interestingly, despite the severe phenotype, the c-Cbl mutation did not enhance FLT3-ITD protein levels or the downstream activity of signal transducer and activator of transcription 5. Rather, the severe leukemia was promoted by greater activity in additional signaling pathways that involved non-FLT3 c-Cbl targets. These included enhanced c-Kit signaling that promoted elevated activity of the phosphoinositide 3-kinase pathway. This study has highlighted the importance of wild-type signaling pathways contributing to leukemia development and suggests that pharmacological manipulation of these pathways may be of therapeutic benefit to control disease progression.


    Potential targeting of B-cell lymphoma 2–associated AthanoGene-1 (BAG-1) in poor responding pediatric AML patients
    Aveic et al., pages 180–190.

    Although huge improvements have been made in the outcome of pediatric acute myeloid leukemia (AML), a significant number of patients still relapse, confirming that standard chemotherapy is not enough. There are several factors that may cause leukemic cells to escape the effects of cytotoxic drugs, and major among them is a failure in apoptosis activation. In the current work, Aveic et al. studied the B-cell lymphoma (BCL) 2–associated AthanoGene-1 (BAG-1), which is shown in the study to be a crucial antiapoptotic protein in AML. The authors demonstrate that the BAG-1 protein is overexpressed in a subgroup of AML patients that showed poor prognosis. The chemical inhibition of BAG-1 by Thioflavin S (which has been shown to interfere with BAG1 function) or BAG-1 silencing improved leukemia cell death by enhancing leukemic cells' sensitivity to conventional drugs. In addition, the authors report synergy between Thioflavin S and conventional chemotherapeutics and between the BCL2 inhibitor ABT-737 and Thioflavin S. In addition, the article reveals that two cellular pathways behind the activation of cell apoptosis, BCL-2 and endoplasmic reticulum stress and unfolded protein response, were both altered after BAG-1 depletion. These findings suggest that BAG-1 targeting could be evaluated as an innovative treatment that may decrease leukemia chemoresistance. The authors support the development and use of specific BAG-1 inhibitors in combination with standard chemotherapy drugs to reduce relapse and improve outcome in pediatric AML patients.


    Autophagy regulates hematopoietic stem and progenitor cell cycle
    Cao et al., pages 229–242.

    Autophagy (or autophagocytosis) is the basic catabolic mechanism that involves cell degradation of unnecessary or dysfunctional cellular components through the actions of lysosomes. The breakdown of cellular components promotes cellular survival during starvation by maintaining cellular energy levels. In this manuscript, Cao et al. explored the role of autophagy in regulating the cell cycle of mouse hematopoietic stem and progenitor cells (HSPCs) using in vivo and ex vivo experimental systems as well as genetically modified mouse models. They show that autophagy regulates the cell cycle of HSPCs in a nutrient-dependent manner. Autophagy signaling under nutrient rich conditions were not upregulated in HSPCs, and cyclin D3 maintained a high level, which promoted cell-cycle entry and cell cycling of HSPCs; however, upon nutrient stress, autophagy of early signaling was activated, which in turn triggered ubiquitinational degradation of cyclin D3 to slow down the cell-cycle entry and G1/S transition of HSPCs, maintaining a proper cell cycling rate. Therefore, autophagy signaling accelerates or decelerates the cell cycle of HSPCs by recruiting ubiquitination machinery to upregulate or downregulate cyclin D3, depending on the nutrient supply. This study nicely demonstrates that autophagy responds to the nutrient supply to adjust the cell cycle and maintain the appropriate quiescence and self-renewal of hematopoietic stem cells as well as cell cycling of HSPCs, which is essential for a functioning hematopoietic system during adult life.

    Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase
    Yamanishi et al., pages 207–214.

    Drug resistance remains a serious problem in leukemia therapy. In this study, Yamanishi et al. investigated the drug resistance mechanism from the viewpoint of epigenetics. Among newly developed nucleoside antimetabolites, clofarabine has broad cytotoxic activity showing therapeutic promise and is currently approved for relapsed acute lymphoblastic leukemia. To investigate the mechanisms responsible for clofarabine resistance, the authors established two clofarabine-resistant lymphoblastic leukemia cell lines from parental lines. They found that expression of deoxycytidine kinase (dCK), which phosphorylates clofarabine to exert cytotoxicity, in clofarabine-sensitive and -resistant cells, showed significant decreased expression of dCK RNA in clofarabine-resistant cells compared with sensitive cells. Interestingly, there was no difference between clofarabine-sensitive and -resistant cells in the methylation status of CpG islands of the dCK promoter and expression of MDR1, MRP1, and ABCG2. Total histone, histone H3, and histone H4 acetylation on ChIP assay were significantly decreased in resistant cells. The authors then examined the effects of melatonin in clofarabine-resistant cells. Melatonin is an indolamine that functions in the regulation of chronobiological rhythms to exert cytotoxic effects. Melatonin treatment led to increased cytotoxicity with clofarabine in resistant cells via increased acetylation, which is another histone deacetylase inhibitor. Melatonin is readily available in the clinic and may be a useful candidate for overcoming clofarabine resistance. Based on the data presented, combination therapy with cytotoxic drugs and histone deacetylase inhibitor might be useful in the clinic for enhancement of therapeutic efficacy in relapsed or refractory leukemia.

    April 2015
    Csf1r collaborates with a C-terminal mutant of C/EBPα to develop aggressive AML
    Togami et al., pages 300–308.

    CCAAT-enhancer-binding protein (C/EBPα) is a transcription factor that regulates proliferation and differentiation of myeloid cells. Two types of C/EBPα mutations are found in patients with acute myeloid leukemia (AML). It has been previously demonstrated, by using either a mouse bone marrow transplantation model or a knock-in mouse, that a C-terminal mutant of C/EBPα(C/EBPα-Cm) alone induces AML and that it collaborates with an N-terminal mutant of C/EBPα(C/EBPα-Nm) in the efficient induction of AML. In this study, Togami et al. investigate the molecular mechanisms underlying C/EBPα-Cm–induced leukemogenesis. By analyzing gene expression profiles of C/EBPα-Cm– and mock-transduced c-Kit+Sca-1+Lin− cells, they identified Csf1r as a gene downregulated by C/EBPα-Cm. In addition, leukemic cells expressing C/EBPα-Cm exhibited low levels of Csf1r in mice. The authors then tested the possibility that the downregulated expression of Csf1r plays critical roles in leukemogenesis, given that Csf1r is required for myeloid differentiation. However, in contrast to their expectation, Csf1r overexpression collaborated with C/EBPα-Cm in inducing fulminant AML with leukocytosis with shorter latencies compared to those of AML induced by C/EBPα-Cm alone. These results suggest that C/EBPα-Cm–mediated downregulation of Csf1r negatively regulates the progression of myeloid malignancies involving C/EBPα-Cm, and may relate to the fact that Csfr1 is a maker of leukemic stem cell in the mouse leukemia model induced by MOZ-TIF2. Further experiments using the C/EBPα-Cm–induced leukemia model will help us understand the molecular mechanisms by which C/EBPα-Cm–induced leukemia in mice and identify novel therapeutic targets.


    BIRB796 stimulates hematopoietic progenitor stem cell growth in FANCA
    Svahn et al., pages 295–299.

    Bone marrow failure, the main cause of mortality and morbidity in Fanconi anemia (FA), has been largely related to overproduction of tumor necrosis factor α (TNF-α), to which FA stem- and progenitor-cells are hypersensitive. It is known that TNF-α suppression improves the growth of patients' hematopoietic progenitor cells and, in nonhuman experimental settings, it was shown that TNF-α overproduction involves the Toll-like receptor (TLR) 4/8 and p38 mitogen-activiated protein kinase (MAPK) pathway. In this study, Svahn et al. attempted to ameliorate the FA pathway by perturbation of p38 MAPK. The work was conducted on primary human FA complementation group A (FANCA)-deficient monocytes from nine patients and shows that: (i) inhibition of p38 MAPK reduces TLR4 and 7/8-mediated TNF-α production; (ii) inhibitors of p38MAPK improve in vitro erythropoiesis; and (iii) this effect occurs on auxiliary cells (monocytes) and not directly on CD34+ cells. The two latter findings are novel and important for two reasons. The first is that translation to patients' primary cells confirms the same findings obtained on cell lines and mice. This may not always be true; FANCA mice, for example, do not have detectable developmental abnormalities. Therefore, “real ground” confirmation supports continuation of this research. The second reason is that, not only did the authors show the positive effect of inhibition of p38 MAPK on FA erythropoiesis, but they also identified the cellular target of this inhibition. This is important to direct the effect of future compounds counteracting marrow failure on a selective cell target preserving CD34+ cells, which is a severely hampered cell population in FA. At large, these findings might be also useful in other marrow failure disorders like acquired aplastic anemia, in which TNF-α is known to play an important pathogenic role.


    The antimalarial drug artemisinin depletes erythrocytes
    Yang et al., pages 331–341.

    Artemisinin is a major antimalarial drug due to its extraordinary efficacy. However, hemolytic anemia is an evident adverse effect for which underlying mechanisms are unclear. Through a small-molecule screen in zebrafish embryos, Yang et al. found in this study that artemisinin treatments led to diminishing red blood cells but had little to no effect on hematopoietic stem cells and myeloid cells. RNA-Seq revealed that artemisinin suppressed a cluster of genes in the heme biosynthesis and globin synthesis pathways, including the gata 1 regulated genes alas2, urod, fech, and ppox. Artimisinin treatment resulted in erythroid cell apoptosis in both zebrafish and human K562 cell-differentiated red blood cells. Importantly, artemisinin suppressed the ectopic expression of erythroid genes in a zebrafish model of polycythemia vera, a blood disorder in which the bone marrow produces too many erythrocytes. This study provides not only a novel insight into the pharmacologic action of artemisinin on differentiated erythroids but also its potential utility in the intervention and therapy on polycythemia vera.

    Bone marrow failure in C57BL/6 mice
    Chen et al. pages 256–267.

    Murine models of immune-mediated bone marrow (BM) failure have been previously developed with proven utility in the study of disease pathophysiology. However, important elements, such as inciting antigens that initiate autoimmune responses and key molecules that direct T cell lodging, remain uncharacterized. In this study, Chen et al developed a new model of immune-mediated BM failure in C57BL/6 (B6) mice through sublethal irradiation and infusion of allogeneic lymphocytes from major histocompatibility complex–mismatched Friend leukemia virus B/N (FVB) donors. Recipient animals underwent oligoclonal cytotoxic T cell expansion and activation along with significant elevations in inflammatory cytokines and chemokines, leading to severe marrow hypoplasia and fatal pancytopenia. This new model establishes a useful platform that could be extended to a large array of gene knockout and transgenic stocks readily available on the B6 strain background. As proof, B6 mice carrying the lpr mutation deficient in the apoptotic receptor Fas (B6-Fas−/−) were tested in the study. B6-Fas−/− mice showed significant attenuation in BM destruction when treated with the same levels of irradiation and allogeneic FVB lymphocyte infusion. Extension of this model to other B6-based knockout and transgenic mutants will help define the roles of individual genes and their products in the development of immune-mediated BM failure. This is needed to understand the mechanisms behind aplastic anemia and other forms of BM failure and treat patients with these devastating diseases.

    This post has not been tagged.

    Share |
    PermalinkComments (0)

    Inside Experimental Hematology: January and February 2015

    Posted By Connections Editor, Friday, February 27, 2015
    Updated: Monday, February 23, 2015


    An ALL xenograft model that simulates the process of clonal selection of chemoresistant clones
    Nowak et al., pages 32-93.

    The combination of high throughput molecular techniques such as next generation sequencing and copy number micro arrays in combination with xenotransplantation models have revealed that the leukemic cell pool of patients suffering from acute lymphoblastic leukemia (ALL) is not only composed of a sequentially developed dominant clone, but also of a disturbingly large collection of additional highly variable subclonal populations with a complex branching architecture of ancestry. This subclonal diversity, which is formed by a high genetic plasticity of ALL cells, is thought to constitute a reservoir for disease relapse and for cell populations resistant to therapy. This study by Nowak et al tested the feasibility of simulating the process of clonal selection of chemoresistant ALL clones in an in vivo xenograft model. Exposing ALL cells to the selective pressure of chemotherapy led to a rapid outgrowth of clones harboring genomic lesions conferring resistance. Even by next-generation deep sequencing, an emerging chemoresistant clone could not be detected in the samples before drug selection. This finding shows a need to further investigate the genetic plasticity of ALL cells under treatment with chemotherapy to elucidate the dynamics by which resistant subclones emerge. The presented model for induction of chemoresistance provides a platform for performing such studies.

    Mixed chimerism in C3a-deficient mice
    Baskiewicz-Ha1asa et al., pages 14-22

    Transplantation tolerance is an important goal in the effort to reduce long-term morbidity and mortality in organ transplant recipients. Mixed chimerism promises transplant tolerance because
    donor-derived antigen-presenting cells migrate to the thymus, present donor antigens to developing recipient thymocytes, and promote the elimination of donor reactive cells through negative selection. Following up on recent studies showing that the C3a-complement component plays a major role in hematopoietic cell circulation and attraction to hematopoietic niches after
    transplantation, Ba_skiewicz-Ha1asa et al. investigated in this study the role of C3a in immune tolerance induction in a chimeric mice model. The analysis of mixed chimerism rate in peripheral blood leukocytes during the 20-week experiment revealed that stable multilineage mixed chimerism was not effectively established in C3a_/_ mice, in contrast to wild-type animals. The tolerance to donor antigens (Balb/c) related to mixed chimerism was also not achieved in C3a_/_ mice, as it was observed employing lymphocytes expressing Vb5 and Vb11 TCRs measurement and skin graft acceptance analysis. The present study demonstrates that C3a is essential for achieving stable mixed chimerism and resulting transplant tolerance. Although the levels of hematopoietic stem and progenitor cells were comparable in C3a_/_ and wild-type mice, the hematopoietic environment in C3a-deficient animals was defective for engraftment of transplanted cells. Because blocking C3a anaphylatoxin has been considered as a potential technique to avoid graft rejection, the authors suggest that blocking C3a might not be applicable in transplantation procedures that are aimed at mixed chimerism.

    Donor chimerism in CD25D-activated leukocytes as a predictor of GvHD after stem cell transplantation
    Martínez -Laperche et al., pages 4-13

    Development of severe graftvs-host disease (GvHD) remains the main complication of hematopoietic stem cell transplantation.CD3þ T lymphocytes (TL) chimerism is currently the cornerstone of leukocyte lineage chimerism analysis for the evaluation of events related to the development of GvHD. However, the TL subset may include both alloreactive and naive cells, what underscores the need to further dissect the TL subset, targeting activated leukocytes (AL) for chimerism studies, since only alloreactive cells would be considered in the analysis. In this study, Martínez -Laperche et al. evaluated the impact of the status of ALs (CD25þ) chimerism on the incidence and clinical course of GvHD in allogeneic transplant recipients after myeloablative conditioning. This retrospective study shows that the analysis of chimerism in AL at day 30 and day 90 after stem cell tranplantation adds to the study of TL and could be useful for the improved anticipation of acute GvHD and chronic GvHD, respectively. The association between
    chimerism in AL and GvHD would aid in clinical decision-making by allowing early post-transplant modification of immunomodulatory therapies.


    Increase level of intact CXCL12 in the spleen of patients with myelofibrosis: a mechanism underlying the development of extramedullary hematopoiesis
    Wang et al., pages 100-109

    Myelofibrosis (MF) is characterized by the constitutive mobilization of hematopoietic stem and progenitor cells (HSCs/HPCs) and the establishment of extramedullary hematopoiesis (EMH). The mechanisms underlying this abnormal HSC/HPC trafficking pattern remain poorly understood. In this study, Wang and coworkers identified a possible mechanism by which MF CD34+ cells lodge in the spleens of MF patients, eventually leading to the development of EMH. The authors observed a dramatically higher number of splenic MF CD34+ cells that migrated in response to splenic homogenate supernatant (plasma) of MF patients, as compared with peripheral blood (PB) MF plasma. They documented that the concentration of the intact HSC/HPC chemoattractant CXCL12 was greater in splenic MF plasma than PB MF plasma, as quantified using mass spectrometry. By contrast, comparable concentrations of the four functionally inactive truncated products of CXCL12, which are due to proteolytic degradation by serine proteases, were detected in both splenic and PB MF plasmas. The authors further showed that the treatment with an anti-CXCL12 neutralizing antibody resulted in a reduction in the degree of migration of splenic MF CD34+ cells toward both PB and splenic MF plasma, validating the role of CXCL12 as a functional chemoattractant. Their data indicate that the MF splenic microenvironment is characterized by increased levels of intact, functional CXCL12, which contributes to the homing of MF CD34+ cells to the spleens, rather than the marrows, of MF patients, ultimately leading to EMH in the spleen. Therapeutic strategies that would be capable of reversing such pathological chemokine gradients might represent a possible means of correcting the abnormal cellular trafficking characteristic of MF-HSC/HPC and delaying disease progression. 


    A novel anti-HLA monoclonal antibody with anti-GVHD activity
    Nakauchi et al., pages 79-88

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) using cord blood or haploidentical donor cells is a promising alternative option for patients who cannot find a human leukocyte antigen (HLA)-matched donor. However, HLA-mismatched allo-HSCT may be complicated by graft-versus-host disease (GVHD), a major cause of nonrelapse mortality mediated by alloreactive T cells. Although several agents have been developed for effective control of GVHD, serious side effects are the major issues to be addressed. In this paper, Nakauchi et al. established a novel therapeutic approach to GVHD using allele-specific anti-HLA monoclonal antibodies (ASHmAbs) that specifically recognize donor-derived cells and cause their death. One such ASHmAb against HLA-A*02:01 (A2-kASHmAb) was examined for its effectiveness in preventing disease in a xenogeneic GVHD mouse model. To induce fatal GVHD, nonirradiated immunodeficient mice were injected with healthy-donor human peripheral blood mononuclear cells with or without expression of HLA-A*02:01. Besides the induction of complement-dependent cell death on their target cells in vitro, the administration of the allele-specific anti-HLA antibody effectively ameliorated the GVHD symptoms of the xenogeneic nonirradiated immunodeficient mice and markedly improved their survival. Furthermore, the authors observed the recovery of human blood-cell chimerism after the antibody treatment, indicating that human hematopoietic stem cells were preserved. This study is the first reported instance of the effectiveness of a cytotoxic anti-HLA antibody against GVHD. This novel therapeutic approach may offer hope for effective treatment of GVHD, favorably influencing the outcome of allo-HSCT.


    Do osteoclasts have a role in HSC trafficking?
    Rao et al., pages 110-114

    The role of osteoclasts in regulating hematopoietic stem/progenitor cell (HSPC) trafficking in the bone marrow is controversial. Initial reports suggested that osteoclasts promote HSPC egress from the bone marrow. On the other hand, genetic or pharmacologic inhibition of osteoclast activity is associated with accentuated granulocyte colony–stimulating factor (G-CSF)-induced HSPC mobilization. This question has potential clinical relevance, since pharmacologic agents that inhibit osteoclasts are widely used in the clinic to treat osteoporosis. Definitive studies addressing this issue have been limited by the osteopetrosis and extramedullary hematopoiesis associated with transgenic mouse models of osteoclast deficiency. To overcome this limitation, Rao et al. developed in this study two complementary nonosteopetrotic mouse models to assess the impact of osteoclast deficiency on HSPC trafficking. In the first model, they generated Rank−/− fetal liver chimeras in Csf3r−/− recipient mice. These mice have normal osteoclast numbers but the osteoclasts lack G-CSF receptor expression. In the second model, they acutely depleted osteoclasts by treating wild-type mice with osteoprotegrin-Fc (OPG-Fc, Figure). In both models, HPSC mobilization at baseline and after G-CSF treatment was comparable to control mice. These data show that osteoclasts are not required for the efficient retention of HSPCs in the murine bone marrow and are dispensable for HSPC mobilization by G-CSF. According to these data, pharmacologic strategies to augment HSPC mobilization by disrupting osteoclast function are unlikely to be effective.


    Mature adipocytes as potential cell source for therapeutic angiogenesis
    Poloni et al., pages 137-146.

    Mature adipocytes are generally considered terminally differentiated because they have lost their proliferative abilities. However, this group has previously reported that adipocytes can dedifferentiate to mesenchymal stem cells. In this study, Poloni et al. show that human adipocytes can also differentiate toward the endothelial lineage without change in karyotype. The cells formed cord- or tube-like structures when cultured in specific medium and expressed several endothelial marker genes and proteins, such as vascular endothelial growth factor receptor 2, vascular endothelial cadherin, von Willebrand factor, and CD133. The characteristics displayed by the cells may reflect an intrinsic plasticity of mature adipocytes to change into different cell types and, moreover, to revert into an immature phase without any chromosomal alterations. These results also highlight the concept that adipose lineage cells may represent a suitable new cell source for therapeutic angiogenesis in ischemic disease.

    This post has not been tagged.

    Share |
    PermalinkComments (0)
    Page 2 of 4
    1  |  2  |  3  |  4

    Association Management Software Powered by YourMembership  ::  Legal